Ebola drugs and diagnostics under development hold potential for generating significant revenues

LONDON - Nov. 17, 2014 - PRLog -- LONDON, UK, 14^th November 2014: A new report by visiongain calculates that the global market for diagnostic tools, preventative vaccines and therapeutic drugs targeting Ebola will achieve significant growth in the coming years. This analysis and insight appears in visiongain’s latest report The Ebola Report: 2014 Epidemic And R&D Drug Prospects. Visiongain is a leading business intelligence company based in London, UK.

The outbreak of the Ebola virus in West Africa in 2014 has turned the spotlight on drugs and vaccines being developed to combat filoviruses such as the Ebola virus. This has led to many government institutions and not-for profit organisations committing large amounts of resources and effort into supporting the development of a number of vaccines, drugs, and diagnostic tools currently being developed or tested for use in either detecting the presence of the Ebola virus, diagnosing Ebola virus disease (EVD), or drugs and vaccines geared towards preventing and treating the disease. Innovative technologies targeting various sites on the virus and the host cell pathways used by the viruses for replication are being developed.

In addition to currently used diagnostic methods such as virus isolation and reverse transcription polymerase chain reactions (RT-PCR), there are rapid test kits currently under development to facilitate the quick detection of the Ebola virus. There are anti-viral drugs being developed that exhibit both Ebola-specific and broad-spectrum activities. These include drugs such as BCX-4430, TKM-Ebola, and Brincidofovir which has reportedly been used on certain Ebola-infected individuals during the outbreak of the disease in 2014.

Moses Akintomide-Akinwamide, a senior pharmaceutical and medical technology market analyst at Visiongain explains: “There have been attempts to develop both therapeutic drugs and prophylactic vaccines against the Ebola virus over the last few decades. However, the recent outbreak of the virus has led to intensifying efforts to progress these vaccines through safety and efficacy studies in human subjects. Chimpanzee-derived replication-defective adenovirus (ChAd) vaccines and recombinant vesicular stomatitis virus-based (rVSV) vaccines that stimulates low-level immune responses to Ebola virus proteins are being tested and are predicted to start being used on front-line healthcare workers as early as 2015.”

The economic productivity in Sierra Leone, Guinea, and Liberia, the three worst-hit countries, has been greatly impacted upon by the outbreak of Ebola in 2014. The patterns of work and food supply in the three countries as well as the surrounding West African countries have been disrupted. Border closures and other quarantine measures aimed at containing the Ebola outbreak has also led to pressure piling on the little available resources in the region. Manufacturing, export trade, and mining activities in the region have seen operations suspended, while the resulting fear of the disease spreading into other geographical regions has impacted on productivity in many regions around the world. Nonetheless, we note that the increasing level of humanitarian responses to the crisis from various government and not-for-profit organisations, such as Médecins Sans Frontières (MSF) and the World Health Organisation (WHO), has helped to mitigate the socio-economic effects of the outbreak on the affected regions. The desire to provide clinical benefits to future sufferers of Ebola virus disease will be a driving factor that will stimulate growth in the future market for Ebola drugs, vaccines, and diagnostic tools.

Visiongain’s report provides the global outlook for diagnostic tools, preventative vaccines and therapeutic drugs being developed or tested for use against the Ebola virus and combating Ebola virus disease. The historical trends in the origin and spread of Ebola virus disease are examined together with projections for future spread of the diseases as well as an explanation of the routes of transmission used by the virus. The report also includes analysis of strengths and weaknesses of strategies being used to help contain the spread of EVD. Analysis and projections for key pharmaceutical products currently being used or under development for Ebola diagnosis, Ebola prevention, and treatment are provided in the report. The report also includes interviews with key opinion leaders in the industry sharing their views on current trends in Ebola diagnosis, prevention, and treatment, and the unmet needs in the market.

The Ebola Report: 2014 Epidemic And R&D Drug Prospects adds to visiongain’s extensive range of analytical reports on industries and markets in healthcare.

For sample pages and further information concerning the visiongain report The Ebola Report: 2014 Epidemic And R&D Drug Prospects please visit: https://www.visiongain.com/Report/1351/The-Ebola-Report-2014-Epidemic-And-R-D-Drug-Prospects

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com

Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.